STOCK TITAN
  1. Home
  2. Sec-filings
  3. LMAT
  4. [Form 4] LEMAITRE VASCULAR INC Insider Trading Activity

LeMaitre Vascular (NASDAQ: LMAT) CEO receives dividend equivalent rights grants

Filing Impact
(Neutral)
Filing Sentiment
(Neutral)
Form Type
4

Rhea-AI Filing Summary

LeMaitre Vascular’s Chairman and CEO, George W. LeMaitre, reported routine compensation-related awards rather than market trades. On March 26, 2026, he acquired several blocks of dividend equivalent rights, each economically equal to one share of LeMaitre Vascular common stock.

The rights accrued automatically on earlier restricted stock unit and performance share unit awards granted in December 2022, 2023, and 2024, and they will vest proportionately with those underlying awards. No open-market buying or selling occurred, and the transactions do not change cash holdings.

Positive

  • None.

Negative

  • None.
Insider LeMaitre George W
Role Chairman and CEO
Type Security Shares Price Value
Grant/Award Dividend Equivalent Rights 3.392 $0.00 --
Grant/Award Dividend Equivalent Rights 3.392 $0.00 --
Grant/Award Dividend Equivalent Rights 5.799 $0.00 --
Grant/Award Dividend Equivalent Rights 6.949 $0.00 --
Grant/Award Dividend Equivalent Rights 8.482 $0.00 --
Grant/Award Dividend Equivalent Rights 9.611 $0.00 --
Grant/Award Dividend Equivalent Rights 14.219 $0.00 --
Holdings After Transaction: Dividend Equivalent Rights — 45.323 shares (Direct)
Footnotes (1)
  1. These dividend equivalent rights accrued on a restricted stock unit award granted on 12/12/2022 and vest proportionately with such award. Each dividend equivalent right is the economic equivalent of one share of the Issuer's common stock. These dividend equivalent rights accrued on a performance share unit award granted on 12/12/2022 and vest proportionately with such award. Each dividend equivalent right is the economic equivalent of one share of the Issuer's common stock. These dividend equivalent rights accrued on a restricted stock unit award granted on 12/8/2023 and vest proportionately with such award. Each dividend equivalent right is the economic equivalent of one share of the Issuer's common stock. These dividend equivalent rights accrued on a performance share unit award granted on 12/8/2023 and vest proportionately with such award. Each dividend equivalent right is the economic equivalent of one share of the Issuer's common stock. These dividend equivalent rights accrued on a restricted stock unit award granted on 12/6/2024 and vest proportionately with such award. Each dividend equivalent right is the economic equivalent of one share of the Issuer's common stock. These dividend equivalent rights accrued on a performance share unit award granted on 12/6/2024 and vest proportionately with such award. Each dividend equivalent right is the economic equivalent of one share of the Issuer's common stock. These dividend equivalent rights accrued on a restricted stock unit award granted on 12/10/2025 and vest proportionately with such award. Each dividend equivalent right is the economic equivalent of one share of the Issuer's common stock.
Dividend equivalent rights grant 3.3921 rights Granted March 26, 2026; each equal to one common share
Dividend equivalent rights grant 5.7990 rights Granted March 26, 2026 as derivative award
Dividend equivalent rights grant 8.4824 rights Granted March 26, 2026; tied to prior RSU award
Largest dividend equivalent grant 14.2186 rights Granted March 26, 2026; economic equivalent of 14.2186 shares
Number of acquisition transactions 7 transactions All coded A for grant/award acquisitions of derivatives
Dividend Equivalent Rights financial
"These dividend equivalent rights accrued on a restricted stock unit award"
Dividend equivalent rights are promises that mirror the cash payments shareholders get from a company’s profits, but they are paid to holders of certain awards (like stock options or restricted stock units) rather than to actual shares. Think of them as a paycheck top‑up that matches dividends while the award is not yet a real stock, and they matter to investors because they add to employee compensation costs and potential share dilution, affecting company profitability and per‑share value.
restricted stock unit financial
"accrued on a restricted stock unit award granted on 12/12/2022"
A restricted stock unit is a promise from a company to give an employee shares of stock after certain conditions are met, like staying with the company for a set amount of time. It’s like earning a bonus that turns into company stock once you’ve proven your commitment, making it a way to motivate and reward employees.
performance share unit financial
"accrued on a performance share unit award granted on 12/8/2023"
A performance share unit (PSU) is a form of executive or employee pay that promises shares (or the cash value of shares) only if the company meets specific performance targets over a set period. Think of it like a bonus cheque that only arrives if the company hits agreed goals — it aligns managers’ rewards with business results and signals to investors how leadership is being incentivized to grow value over time.
economic equivalent of one share financial
"Each dividend equivalent right is the economic equivalent of one share"
Form 4 Insider Transactions: What Each Field Means →
SEC Form 4
FORM 4UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number:3235-0287
Estimated average burden
hours per response:0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
LeMaitre George W
(Last)(First)(Middle)
C/O LEMAITRE VASCULAR, INC.
63 SECOND AVENUE
(Street)
BURLINGTON MASSACHUSETTS 01803
(City)(State)(Zip)
UNITED STATES
(Country)		2. Issuer Name and Ticker or Trading Symbol
LEMAITRE VASCULAR INC [ LMAT ] 		5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
XDirector10% Owner
XOfficer (give title below)Other (specify below)
Chairman and CEO
2a. Foreign Trading Symbol
3. Date of Earliest Transaction (Month/Day/Year)
03/26/2026		6. Individual or Joint/Group Filing (Check Applicable Line)
XForm filed by One Reporting Person
Form filed by More than One Reporting Person
4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year)2A. Deemed Execution Date, if any (Month/Day/Year)3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeVAmount(A) or (D)Price
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year)3A. Deemed Execution Date, if any (Month/Day/Year)4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year)7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeV(A)(D)Date ExercisableExpiration DateTitleAmount or Number of Shares
Dividend Equivalent Rights(1)03/26/2026A3.3921 (1) (1)Common Stock3.3921$045.3232D
Dividend Equivalent Rights(2)03/26/2026A3.3921 (2) (2)Common Stock3.3921$044.6145D
Dividend Equivalent Rights(3)03/26/2026A5.799 (3) (3)Common Stock5.799$050.492D
Dividend Equivalent Rights(4)03/26/2026A6.9494 (4) (4)Common Stock6.9494$052.6417D
Dividend Equivalent Rights(5)03/26/2026A8.4824 (5) (5)Common Stock8.4824$043.354D
Dividend Equivalent Rights(6)03/26/2026A9.6109 (6) (6)Common Stock9.6109$042.4825D
Dividend Equivalent Rights(7)03/26/2026A14.2186 (7) (7)Common Stock14.2186$014.2186D
Explanation of Responses:
1. These dividend equivalent rights accrued on a restricted stock unit award granted on 12/12/2022 and vest proportionately with such award. Each dividend equivalent right is the economic equivalent of one share of the Issuer's common stock.
2. These dividend equivalent rights accrued on a performance share unit award granted on 12/12/2022 and vest proportionately with such award. Each dividend equivalent right is the economic equivalent of one share of the Issuer's common stock.
3. These dividend equivalent rights accrued on a restricted stock unit award granted on 12/8/2023 and vest proportionately with such award. Each dividend equivalent right is the economic equivalent of one share of the Issuer's common stock.
4. These dividend equivalent rights accrued on a performance share unit award granted on 12/8/2023 and vest proportionately with such award. Each dividend equivalent right is the economic equivalent of one share of the Issuer's common stock.
5. These dividend equivalent rights accrued on a restricted stock unit award granted on 12/6/2024 and vest proportionately with such award. Each dividend equivalent right is the economic equivalent of one share of the Issuer's common stock.
6. These dividend equivalent rights accrued on a performance share unit award granted on 12/6/2024 and vest proportionately with such award. Each dividend equivalent right is the economic equivalent of one share of the Issuer's common stock.
7. These dividend equivalent rights accrued on a restricted stock unit award granted on 12/10/2025 and vest proportionately with such award. Each dividend equivalent right is the economic equivalent of one share of the Issuer's common stock.
/s/ Laurie A. Churchill, Attorney-in-fact03/30/2026
** Signature of Reporting PersonDate
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

Source: View Original Filing on SEC EDGAR

FAQ

What insider activity did LeMaitre Vascular (LMAT) report for George W. LeMaitre?

LeMaitre Vascular reported that Chairman and CEO George W. LeMaitre received several grants of dividend equivalent rights on March 26, 2026. These awards are compensation-related derivatives tied to existing stock unit grants, not open-market stock purchases or sales.

What are dividend equivalent rights in the LeMaitre Vascular (LMAT) Form 4?

Dividend equivalent rights are awards that give the holder the economic equivalent of one common share for each right. In this filing, they accrued on prior restricted stock unit and performance share unit awards and will vest in step with those underlying equity grants.

How many dividend equivalent rights did the LeMaitre Vascular (LMAT) CEO receive?

The CEO reported seven acquisition transactions, including grants of 3.3921, 5.7990, 6.9494, 8.4824, and 14.2186 dividend equivalent rights. Each right corresponds economically to one share of LeMaitre Vascular common stock under the company’s existing equity awards.

Were there any stock sales or open-market purchases in this LeMaitre Vascular (LMAT) Form 4?

No. All reported entries are coded A for grants or awards of derivative securities, specifically dividend equivalent rights. The summary shows no open-market buying or selling of common stock and no reported dispositions related to tax withholding or gifts.

What equity awards do the LeMaitre Vascular (LMAT) dividend equivalent rights relate to?

The dividend equivalent rights accrued on restricted stock unit and performance share unit awards originally granted on December 12, 2022, December 8, 2023, December 6, 2024, and December 10, 2025. They will vest proportionately as those underlying awards vest over time.

Do the dividend equivalent rights in LMAT’s Form 4 vest immediately?

No. The footnotes state that these dividend equivalent rights vest proportionately with the related restricted stock unit and performance share unit awards. This means vesting follows the same schedule as the original equity grants rather than being fully vested on the grant date.